JP Morgan Healthcare ConferenceJanuary 11, 2021

Amir AghdaeiPresident & CEO

Envista

1

Forward Looking Statements

2

Certain statements in this presentation are “forward-looking” statements within the meaning of the federal securities laws. There are a number of important factors that could cause actualresults, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any suchforward-looking statements. These factors include, among other things, the impact of the COVID-19 pandemic, the conditions in the U.S. and global economy, the markets served by us and thefinancial markets, the impact of our debt obligations on our operations and liquidity, developments and uncertainties in U.S. policy stemming from the U.S. administration, such as changes inU.S. trade and tariff policies and the reaction of other countries thereto, contractions or growth rates and cyclicality of markets we serve, fluctuations in inventory of our distributors andcustomers, loss of a key distributor, our relationships with and the performance of our channel partners, competition, our ability to develop and successfully market new products and services,the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices andthe health care industry), the results of our clinical trials and perceptions thereof, penalties associated with any off-label marketing of our products, modifications to our products that require newmarketing clearances or authorizations, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummateappropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions, contingent liabilities relating toacquisitions, investments and divestitures, significant restrictions and/or potential liability based on tax implications of transactions with Danaher, security breaches or other disruptions of ourinformation technology systems or violations of data privacy laws, our ability to adequately protect our intellectual property, the impact of our restructuring activities on our ability to grow, risksrelating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicableto multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, our ability to implement and maintain effectiveinternal control over financial reporting, risks relating to product, service or software defects, risks relating to product manufacturing, commodity costs and surcharges, our ability to adjustpurchases and manufacturing capacity to reflect market conditions, reliance on sole or limited sources of supply, the impact of regulation on demand for our products and services, labormatters, international economic, political, legal, compliance and business factors (including the impact of the United Kingdom’s decision to leave the EU), disruptions relating to war, terrorism,widespread protests and civil unrest, man-made and natural disasters, public health issues and other events, pension plan costs, and our ability to attract, develop and retain talentedexecutives and other key employees. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SECfilings, including our Annual Report on Form 10-K for fiscal year 2019 and our Quarterly Reports on Form 10-Q. These forward-looking statements speak only as of the date of this presentationand except to the extent required by applicable law, we do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future eventsand developments or otherwise.

24%

48%

22%

6%

EM NA W-EU ROW

All financial metrics based on 2019 unless otherwise indicated; all pie chart percentages are % of 2019 sales; ROW = rest of world

1: Adj. EBITDA Margin is a non-GAAP financial measure. For a reconciliation to the most directly comparable GAAP measure, please see Appendix.

Revenue by segment

Revenue by channel

Revenue by geography

Outstanding brand portfolio with decades of industry expertise

Strong global growth drivers:• Aging of global population • Growing middle class in

Emerging Markets• Digitization of the dental practice• Increased focus on aesthetics

51%

49%

Equipment & Consumables

Specialty Products & Technologies

>70% Consumables

Distributor50%

Direct50%

TOTAL 2019 REVENUE

2019 ADJ. EBITDA MARGIN1

$2.8B

Mid-teens

2019 GROSS MARGIN~55%

3

Portfolio positioned for “new normal”

85% of Envista revenue in consumables or small equipment

Orthodontics

Implants & Biomaterials

Consumables

Small Equipment

Large Imaging Equipment

Treatment Units

4

Total Sales:~$1.3B

EBITDA Margin*: >20%

Channel: >90% Direct

Total Sales: ~$1.4B

EBITDA Margin*: >10%

Channel: >85% Distribution

Equipment and ConsumablesSpecialty Products & Technologies

All financial metrics based on 2019 unless otherwise indicated* EBITDA Margin is a non-GAAP financial measure. For a reconciliation to the most directly comparable GAAP measure, please see Appendix.

Our foundation

5

PurposeWHY WE ARE HERE

PromiseWHAT WE PROMISE

We partner with professionals to improve lives We champion creators of confidenceCore Values

WHAT WE BELIEVE

Customer Centricity Innovation Respect Continuous

Improvement LeadershipPowered by

Envista Business SystemHOW WE WORK

Lean Innovation Growth Leadership

EBS drives Envista transformation

EBS driving significant transformation over the past five years

EBS Pillar Pre - 2016 2020Lean Complex

organizationOrganization simplification - 10 OpCos to 3 OpCos- >230 sites to <100 sites- Execution of $100M permanent cost reduction initiatives

Innovation Limited innovation and new product launches

Accelerated innovation- DTX, N1, and Spark now commercially launched- Broader roll out continuing in ’21

Growth Competing brands Portfolio simplification- Imaging/Treatment Unit brands from 11 to 5 - Exit of lower growth/margin business including Pelton & Crane and

Latin America Treatment Unit businesses

Leadership Lack of continuity in leadership

- Core leadership team in place since 2016- >200 years combined Envista and Dental market experience

6

Leveraging EBS to create long-term value

Positioned to accelerate growthas a leader in some of the most attractive segments of Dental

Significant opportunity to

expand marginsthrough operating

leverage, productivity initiatives and

improving portfolio mix

Flexible capital structure and strong cash flow profile for

M&A to further improve growth

profile

Building a differentiated Envista 7

Driving sustainable long-term core growth*

Clear path to accelerate growth to MSD over time

E&C

2019 Core Growth Long-Term Growth Drivers

• Higher consumable mix – Infection prevention growth / P&C exit

• DTX software driving imaging and integrated workflow adoption

• Greater adoption in implant and orthodontic market

• New product innovation – Spark and N1

Specialty LSD >MSD

-LSD LSD

Envista Flat MSD • Expansion in DSO market• Growing Emerging Markets

presence

8*These are not projections and do not constitute guidance; they are subject to significant business, economic, regulatory and competitive uncertainties and contingencies, many of which are beyond the control of the Company and its management, and are based upon assumptions with respect to future decisions, which are subject to change. Actual results will vary and those variations may be material. Nothing in this presentation should be regarded as a representation by any person that these results will be achieved and the Company undertakes no duty to update this information. Core Growth is a non-GAAP financial measure. For a reconciliation to the most directly comparable GAAP measure, please see Appendix

Growing in Infection Prevention

Infection prevention added >200bps of revenue growth in Q3 2020

Infection Prevention Revenue

2019 Future Target

$175M

$275M+

Geographic Expansion

Market Expansion

Medical share gain

2020 market grew >10% due to increased infection prevention compliance

Leverage global footprint: U.S. is ~80% of Envista infection prevention revenue

New products, capacity and OEM certification to improve share: Envista has <10% share in medical vs. >40% share in Dental

>50%

9

Specialty Products & Technologies

Orthodontics and Implants are significantly underpenetrated markets

500M

15M

Potential cases Actual ortho treatments / year

<3% treated

Orthodontics

4B

200M

<20M

People w/ toothloss

Seek treatment(annually)

Receive implant*(annually)

<10%

Implants

Market Size:$5.5B

Aligner Growth: >20%

B&W Growth: Flat/LSD

Market Size: $5.5B

Market Growth:MSD

10 Source: WHO, iData, Management estimates; (*) Avg. 1.5-2 implants per treatment

How we win in Orthodontics

Building a $400M+ business positioned to grow revenue DD with >20% EBITDA margins*

>20% of 2020E sales from new products launches in past 3 years

Orthodontic Core Sales Growth

2018 2019 Q3 2020

MSDLSD/MSD

DD

B&W Market

• >250% increase in cases in 2H’20E vs 1H’20• >1,000 active orthodontists • Anticipate HSD contribution to orthodontic revenue growthInnovation

Education

Geographic Exposure

Annually >500 events and >75,000 clinicians trained

>70% of 2020E sales outside of US

11*These are not projections and do not constitute guidance; they are subject to significant business, economic, regulatory and competitive uncertainties and contingencies, many of which are beyond the control of the Company and its management, and are based upon assumptions with respect to future decisions, which are subject to change. Actual results will vary and those variations may be material. Nothing in this presentation should be regarded as a representation by any person that these results will be achieved and the Company undertakes no duty to update this information.

How we win in Implants

>1,300 direct “Feet on the Street”; Annually >750 events and >100,000 clinicians trained

Leader in clinical and digital workflow innovation

Expand in higher growth biomaterials/value implant markets, < 20% of Envista implant revenue 2020E

Clinical Advantages

N1 Implant System

• Drill speed 50 rpm vs >1,000 rpm1

• Drill protocol – 80% of implants placed in 2 steps

• Trioval implant shape reduces stress and promotes faster osseointegration2

• Shorter learning curve, easier to train

2020 Progress

• >300 doctors now using in >10 EU countries; 2/3rds repeat customers

• Not yet available for sale in the United States

12

Innovation

Education

Capital Deployment

Innovation and commercial execution to accelerate growth to MSD+ over time*1 Conventional2 Internal pre-clinical data

*These are not projections and do not constitute guidance; they are subject to significant business, economic, regulatory and competitive uncertainties and contingencies, many of which are beyond the control of the Company and its management, and are based upon assumptions with respect to future decisions, which are subject to change. Actual results will vary and those variations may be material. Nothing in this presentation should be regarded as a representation by any person that these results will be achieved and the Company undertakes no duty to update this information.

# Non-ortho employees # Ortho employeesApr '20 Dec '20

Improving margin and investing for growth

Visibility to expand to high-teens and above EBITDA* margin over time

2020 Cost Reduction Program

Headcount Reduction

Indirect Spend and Real Estate

$100Mannualized

savings

Headcount Reduction & Redeployment

Planned investment in Specialty

>$30M $ capacity and commercial

investment ’21 vs ‘19

13

Site consolidation in 2020

Closed >10 sites

Additional MFG Facility

1

*EBITDA is a projection and does not constitute guidance. Actual results will vary and those variations may be material. Nothing in this presentation should be regarded as a representation by any person that these results will be achieved and the Company undertakes no duty to update this information.

>10% >40%

Capital deployment priorities

14 I

Opportunity to thoughtfully deploy capital on M&A while continuing to de-lever

Opportunity to accelerate

2003 - 2015

# M&A deals

2016 - 2020

>25

3

Improving balance sheet

2017 – 2019FCF* >$1B Q3 2019 Q3 2020

$1.3B

$1.1B

$ Net Debt**

~20% reduction

14 *FCF is a non-GAAP financial measures. For a reconciliation to the most directly comparable GAAP measures, please see Appendix.**Net debt is calculated as gross debt, plus bank overdrafts, less debt discounts and issuance costs, and cash.

Consumables and workflow-oriented portfolio

Imaging$0.4B*

Software / Treatment Planning

SpecialtyConsumables

$1.3B*

Traditional Equipment

$0.3B*

Traditional Consumables

$0.6B*

Treatment Units

Instruments/Handpieces

Infection Prevention RestorativeEndodontics

>85% of Envista positioned in high value workflow solutions and consumables15 *All financial metrics based on 2019 unless otherwise indicated; Traditional equipment excludes the revenue from exited treatment center and instrument business

Summary

Transforming Envista into a workflow and consumables focused portfolio

Core sales growth1,2

Flat in 2019 to +MSD long-term

Acquisition growth~$1B free cash flow (2017-2019)

Margin expansion1

Visibility to expand EBITDA margin2

to high-teens and above over time

Continuous improvementEBS is how we work

161 These are not projections and do not constitute guidance; they are growth drivers and are subject to significant business, economic, regulatory and competitive uncertainties and contingencies, many of which are beyond the control of the Company and its management, and are based upon assumptions with respect to future decisions, which are subject to change. Actual results will vary and those variations may be material. Nothing in this presentation should be regarded as a representation by any person that these drivers will be achieved and the Company undertakes no duty to update this information.2 : Core sales growth, free cash flow and EBITDA margin are non-GAAP financial measure. For a reconciliation to the most directly comparable GAAP measure, please see Appendix.

Appendix

Reconciliation of Adjusted EBITDA

(unaudited)($ in millions)

Year EndedDecember 31

2019

Reported Net Earnings (GAAP) $217.6

Interest expense, net 3.5

Income taxes 57.9

Depreciation 39.0

Amortization 89.5

EBITDA (Non-GAAP) $407.5

Accruals for significant legal matters 9.0

Separation costs 4.2

Adjusted EBITDA (Non-GAAP) $420.7

Sales $2,751.6

EBITDA Margin (EBITDA/Sales) 14.8%

Adjusted EBITDA Margin (Adjusted EBITDA/Sales) 15.3%

Reconciliation of EBITDA by segment

(unaudited)($ in millions)

Year Ended December 31

2019

Specialty Products &

Technologies

Equipment & Consumables

Operating profit $227.7 $105.8

Depreciation 17.7 19.6

Amortization 57.7 31.8

EBITDA (Non-GAAP) $303.1 $157.2

Sales $1,342.7 $1,408.9

EBITDA Margin (EBITDA/Sales) 22.6% 11.2%

Reconciliation of Free Cash Flow(unaudited)($ in millions)

Year Ended December 31

2019 2018 2017

Net cash used in investing activities (GAAP) ($78.4) ($75.5) ($54.9)

Net cash provided by (used in) financing activies (GAAP)

($107.7) ($324.6) ($304.2)

Net cash provided by (used in) operating activities (GAAP)

$397.5 $400.1 $359.1

Less: payments for additions to property plant & equipment (capital expenditures) (GAAP)

(77.8) (72.2) (48.9)

Plus: proceeds from sales of property, plant & equipment (capital disposals) (GAAP)

1.6 - 0.1

Free Cash Flow (Non-GAAP) $321.3 $327.9 $310.3

Reconciliation of Core Sales GrowthConsolidated (unaudited) % Change Year Ended December 31, 2019 vs.

Comparable 2018 PeriodTotal sales growth (3.5%)Less the impact of:Discontinued products 1.0%Currency exchange rates 2.5%Core sales growth -%

Specialty Products & TechnologiesTotal sales growth (2.0%)Less the impact of:Discontinued products 1.5%Currency exchange rates 2.0%Core sales growth 1.5%

Equipment & ConsumablesTotal sales growth (4.5%)Less the impact of:Discontinued products 1.0%Currency exchange rates 2.5%Core sales growth (1.0%)

We use the term “core sales” to refer to GAAP revenue excluding (1) sales from acquired businesses recorded prior to the first anniversary of the acquisition (“acquisitions”), (2) sales from discontinued products and (3) the impact of currency translation.Sales from discontinued products includes major brands or products that Envista has made the decision to discontinue as part of a portfolio restructuring. Discontinued brands or products consist of those which Envista (1) is no longer manufacturing, (2) is no longer investing in the research or development of, and (3) expects to discontinue all significant sales within one year from the decision date to discontinue. The portion of sales attributable to discontinued brands or products is calculated as the netdecline of the applicable discontinued brand or product from period-to-period. The portion of GAAP revenue attributable to currency exchange rates is calculated as the difference between (a) the period-to-period change in sales and (b) the period-to-periodchange in sales after applying current period foreign exchange rates to the prior year period. We use the term “core sales growth” to refer to the measure of comparing current period core sales with the corresponding period of the prior year.